floxuridine has been researched along with Carcinoma, Transitional Cell in 3 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 112 patients with pTa or pT1 bladder cancer were eligible for the analysis and were allocated to either an adjuvant group (TURBT+5'-DFUR; n = 47; initial 23 months) or a control group (TURBT alone; n = 65, final 23 months)." | 6.71 | Novel prophylactic effect of doxifluridine in superficial bladder cancer. ( Aoki, A; Baba, Y; Jojima, K; Matsuyama, H; Naito, K; Shimabukuro, T; Suga, A; Suyama, K; Uchiyama, K; Yamamoto, N, 2004) |
| "A total of 112 patients with pTa or pT1 bladder cancer were eligible for the analysis and were allocated to either an adjuvant group (TURBT+5'-DFUR; n = 47; initial 23 months) or a control group (TURBT alone; n = 65, final 23 months)." | 2.71 | Novel prophylactic effect of doxifluridine in superficial bladder cancer. ( Aoki, A; Baba, Y; Jojima, K; Matsuyama, H; Naito, K; Shimabukuro, T; Suga, A; Suyama, K; Uchiyama, K; Yamamoto, N, 2004) |
| "Human solid tumor histocultures represent a clinically relevant experimental system for pharmacodynamic study." | 1.30 | Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. ( Au, JL; Weaver, JR; Wientjes, MG, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuyama, H | 1 |
| Baba, Y | 1 |
| Shimabukuro, T | 1 |
| Uchiyama, K | 1 |
| Aoki, A | 1 |
| Suga, A | 1 |
| Jojima, K | 1 |
| Suyama, K | 1 |
| Yamamoto, N | 1 |
| Naito, K | 1 |
| Weaver, JR | 1 |
| Wientjes, MG | 1 |
| Au, JL | 1 |
| Kubota, Y | 1 |
| Miura, T | 1 |
| Shuin, T | 1 |
| Kinoshita, Y | 1 |
| Hosaka, M | 1 |
| Kondo, I | 1 |
| Moriyama, M | 1 |
| Fukushima, S | 1 |
| Fukuoka, H | 1 |
| Miyai, K | 1 |
1 trial available for floxuridine and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Novel prophylactic effect of doxifluridine in superficial bladder cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cystectomy; Dose | 2004 |
2 other studies available for floxuridine and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Culture Techniques; Drug Screeni | 1999 |
[Phase II study of 5'-DFUR (Furtulon) capsule for bladder cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Squamous | 1991 |